Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Liver Transpl ; 30(10): 1026-1038, 2024 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-38771635

RESUMO

Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with significant morbidity and mortality. While liver transplantation is the definitive treatment, continuous terlipressin infusion for HRS-AKI may provide benefit and, as such, was assessed in a population composed of candidates for liver transplant (LT). Fifty hospitalized LT-eligible patients with HRS-AKI received a single bolus followed by continuous terlipressin infusion. Acute-on-chronic liver failure grade 3, serum creatinine (SCr)>5.0 mg/dL, or Model for End-Stage Liver Disease (MELD) ≥35 were exclusions. Fifty hospitalized patients who received midodrine and octreotide or norepinephrine for HRS-AKI served as a historical comparator cohort. Complete response (CR) was defined as a ≥30% decrease in SCr with end-of-treatment (EOT) SCr≤1.5, partial response as a ≥30% decrease in SCr with EOT SCr>1.5, and nonresponse as a <30% decrease in SCr. CR rate was significantly higher in the terlipressin cohort compared to the historical cohort (64% vs. 16%, p <0.001). Survival, while numerically higher in those who received terlipressin, was statistically similar (D30: 94% vs. 82%, p =0.12; D90: 78% vs. 68%, p =0.37). Renal replacement therapy (RRT) was more common among terlipressin NR than CR and PR (70% vs. 3% vs. 13%, p < 0.001). EOT MELD and SCr were significantly lower within terlipressin cohort (MELD: 19 vs. 25, SCr: 1.4 vs. 2.1 mg/dL, p <0.001). Sixteen of 40 terlipressin-treated patients received LT-alone (terlipressin CR in 10/16). One patient on terlipressin had a hypoxic respiratory failure that responded to diuretics; one possibly had drug-related rash. With continuous terlipressin infusion, a CR rate of 64% was observed with a favorable safety profile. Terlipressin use was associated with lower EOT MELD and SCr than the historical midodrine and octreotide/norepinephrine cohort; LT-alone was accomplished in a high proportion of complete terlipressin responders.


Assuntos
Injúria Renal Aguda , Síndrome Hepatorrenal , Transplante de Fígado , Lipressina , Terlipressina , Vasoconstritores , Humanos , Terlipressina/administração & dosagem , Terlipressina/efeitos adversos , Masculino , Feminino , Transplante de Fígado/efeitos adversos , Pessoa de Meia-Idade , Resultado do Tratamento , Vasoconstritores/administração & dosagem , Vasoconstritores/efeitos adversos , Vasoconstritores/uso terapêutico , Lipressina/análogos & derivados , Lipressina/administração & dosagem , Lipressina/efeitos adversos , Infusões Intravenosas , Síndrome Hepatorrenal/etiologia , Injúria Renal Aguda/etiologia , Injúria Renal Aguda/terapia , Idoso , Creatinina/sangue , Adulto , Octreotida/administração & dosagem , Octreotida/efeitos adversos , Doença Hepática Terminal/cirurgia , Doença Hepática Terminal/mortalidade , Doença Hepática Terminal/diagnóstico , Estudos Retrospectivos , Midodrina/administração & dosagem , Midodrina/efeitos adversos , Midodrina/uso terapêutico , Norepinefrina/administração & dosagem
2.
Contemp Clin Trials Commun ; 36: 101211, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37953795

RESUMO

Background: Hepatorenal syndrome-acute kidney injury (HRS-AKI) carries significant morbidity and mortality among those with end-stage liver disease. Bolus terlipressin for treatment of HRS-AKI received FDA approval in September 2022. US implementation of terlipressin, however, is hindered by the paucity of local data on the optimal patient population and administration mode, as well as the effect on transplant priority. The INFUSE study is designed to evaluate the use of continuous terlipressin infusion among transplant candidates with advanced liver disease and HRS-AKI. Methods: Fifty prospective patients with HRS-AKI will receive a single bolus of terlipressin 0.5 mg followed by continuous infusions of terlipressin from 2 to 8 mg/day for up to 14 days. The cohort will be enriched with those listed, in evaluation, or eligible for liver transplantation, while those with ACLF grade 3, MELD ≥35, and serum creatinine >5.0 mg/dL will be excluded. Fifty patients who received midodrine plus octreotide or norepinephrine for HRS-AKI will serve as a retrospective comparator cohort. Conclusion: The INFUSE study aims to assess the safety and efficacy of continuous terlipressin infusion among largely transplant-eligible patients with HRS-AKI, and to provide US-based data on transplant outcomes. This novel study design simultaneously mitigates terlipressin adverse events while providing renal benefits to patients, thus addressing the unmet medical need of those with HRS-AKI who have limited treatment options and are awaiting liver transplantation in the US.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA